title: Does acid suppressive therapy reduce the risk of laryngeal cancer recurrence?
abstract: OBJECTIVE
  Gastroesophageal reflux disease (GERD) is implicated in laryngeal cancer pathogenesis and recurrence posttherapy. There are currently limited data on the effect of acid suppressive therapy in decreasing the recurrence of laryngeal cancer. Therefore, we conducted this study to identify potential effect of GERD and acid suppressive therapy on recurrences after larynx-preserving therapies.
  
  
  METHODS
  Case control study.
  
  
  METHODS
  Cases and controls, derived from a single tertiary care center, were patients who had newly diagnosed localized laryngeal cancer (T3 or less and absence of nodes) and having undergone larynx-preserving surgery or radiotherapy/chemotherapy were followed between January 1, 2000 and December 31, 2003. Univariable associations were performed for demographics, smoking and alcohol patterns, stage of tumor, initial treatment, surgeon of record, presence of GERD, and the use of acid suppressive medications. Multivariable associations were performed for clinically significant variables.
  
  
  RESULTS
  Of 258 patients with laryngeal cancer, 61 satisfied the selection criteria. Twenty-two of 61 (36%) developed recurrence and constituted cases, whereas 39/61 (64%) did not have recurrence and constituted controls. On univariable analysis, significant factors for decreased recurrences were GERD, hazard ratio 0.24 (95% confidence interval [CI] 0.08-0.71), and acid suppressive therapy, hazards 0.22 (95% CI 0.07-0.66). On multivariable analysis, laryngeal cancer recurrence was significantly less in those on acid suppressive therapy, hazard 0.31 (95% CI 0.13-0.75).
  
  
  CONCLUSIONS
  Acid suppression postlaryngeal cancer therapies may have protective effect on laryngeal cancer recurrences. A prospective study is needed to better define this perceived beneficial effect.
authors.affiliation: Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Ohio, USA.
authors.forename: Mohammed A
authors.initials: MA
authors.lastname: Qadeer
authors.forename: Rocio
authors.initials: R
authors.lastname: Lopez
authors.forename: Benjamin G
authors.initials: BG
authors.lastname: Wood
authors.forename: Ramon
authors.initials: R
authors.lastname: Esclamado
authors.forename: Marshall
authors.initials: M
authors.lastname: Strome
authors.forename: Michael F
authors.initials: MF
authors.lastname: Vaezi
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D054328:Proton Pump Inhibitors
chemical_list: D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors